Pfizer stock may be an attractive stock to hold in your portfolio if you are building a mixed strategy based on both yield and growth.
How much can you make with Pfizer stock?
Get up-to-date and precise information on Pfizer stock with its current price, dividend yield, analysis and our opinion.
This page is for information purposes only and does not constitute investment advice. Remember that investing can be risky.
Want to buy shares in Pfizer: Our key take-aways
Stock exchange: NYSE
- Stock Index: S&P
- Dividend 2021: $1.57
- 2022 Dividend Forecast: $1.6
- 1 year performance: +39.64%
Should I buy Pfizer stock?
It is still worthwhile to own Pfizer shares in 2022 if you want to benefit from a regular return while hoping to realize a capital gain over the longer term.
Pfizer Group pays a dividend to its shareholders every year with a steadily increasing amount and a yield close to 4%.
Moreover, the signals of fundamental and technical analysis as well as the opinions of analysts suggest that the price of this stock will rise over the medium and long-term.
Learn all about stocks and get investing advice online from The Motley Fool.
Investment recommendations and the best stock picks from The Motley Fool Stock Advisor
How can I buy shares in Pfizer ?
To buy Pfizer on the stock market:
- Find an online broker offering stock investments.
- Open your trading account by filling out a simple form.
- Deposit funds into your account.
- Search for the stock
- Place a buy order to add Pfizer to your stock portfolio.
How much are Pfizer shares?
See price chart below to follow Pfizer stock price in real time.
Ready to invest in Pfizer? Shop for through Qtrade.
Why Pfizer shares could go up:
Here we will look at all of the micro and macroeconomic elements in favour of a rising Pfizer share price:
- One of the world leaders in its sector: the Pfizer group is currently one of the largest pharmaceutical companies in the world and has international operations.
- Major innovations: Thanks to strong investments in research and development, the Pfizer Group is able to create innovative products and revolutionize certain treatments.
- Strong international presence: Pfizer has established a strong presence in a large number of countries around the world, enabling the company to reach a broad market of customers.
- Strategic operations: the company regularly carries out strategic operations aimed at acquiring or joining forces with pharmaceutical companies and brands in order to improve its brand image and reputation.
- Strong brand recognition: Pfizer Group is also a globally recognized brand thanks to its strong leadership in the pharmaceutical sector.
- Strong financial strength: Another strength of the Pfizer Group is of course its financial strength as well as its excellent presence on the NYSE and S&P. The group's average turnover is close to 40 billion dollars per year.
- A leader in the fight against Covid-19: the company, which has invested more than 2 billion dollars in the research of a vaccine against the new corinavirus, has managed to pull through and is currently distributing its doses worldwide.
Why Pfizer shares could go down:
Let's now review the weaknesses and threats of Pfizer Group that may represent signals for a decline in its share price:
- Strong competition: despite being one of the leaders in its market, Pfizer faces fierce competition from large global pharmaceutical brands, which reduces its opportunities to increase its market share.
- Legal issues: Pfizer's brand image has recently been tarnished by legal issues and lawsuits.
- Risk of revenue loss: The development of unsuccessful products that do not pass clinical trials can result in significant revenue losses for the company.
- Impactful regulations: The regulatory environment in which Pfizer operates is becoming increasingly stringent, creating new challenges for its global business.
- Exposure to economic downturn: The Group's business may finally be impacted by the global economic downturn, which could lead to a loss of profits, particularly in the European market.
Can I buy Pfizer stock online?
Yes! You can buy Pfizer shares online. For many buys this is the best way to do it. Here's why:
- The commissions are lower
- You can choose your own investments
- You benefit from analysis and decision support tools
- You can invest in stocks directly or through derivatives like ETFs.
How can I sell my Pfizer shares?
You can only sell Pfizer stock using a traditional savings vehicle if you own it first. Short selling is only available through a margin account.
However, you can also speculate on a possible decline in the stock's price through derivatives such as options and CFDs. But here, you will not physically hold these securities and you will not receive a dividend.
What investment vehicles in Canada can hold Pfizer stock?
Pfizer shares can be placed in several different savings vehicles including"
- RRSPs: these registered retirement savings plans offer funds that are accessible at the time of retirement and offer an income tax deferral.
- TFSAs: tax-free savings accounts is an incredibly popular short-and long-term tax-free investment vehicle.
- Margin accounts: This account offers leverage and allows you to borrow against the value of the securities you hold to make other investments. It allows you to sell short.
- Cash accounts: This account allows you to trade stocks on North American markets only.
Buying Pfizer stock can be done in cash from any investment account, simply by purchasing the desired number of shares from your online brokerage platform.
But you also have the option of making a more diversified investment through a fund such as a mutual fund (FCP) or an ETF (Exchange Traded Fund), which combines several assets including Pfizer stock.
Pfizer share price history over 10 years:
Pfizer dividends and payment dates
In 2021, Pfizer Group distributed a dividend of $1.57 per share to its shareholders, which represents a yield of 3.22%
The dividend is paid quarterly, four times a year, most often in January, May, July and November.
Pfizer has paid a dividend to its shareholders without interruption since 1980.
The dividend announced by Pfizer in 2022 for the fiscal year 2021 is expected to be $1.60 per share.
|Dividend: payout 2021||Payout 1||Payout 2||Payout 3||Payout 4|
|Dividend per stock||$0.39 per stock||$0.39 per stock||$0.39 per stock||$0.39 per stock|
|Dividend: payout 2022||Payout 1||Payout 2||Payout 3||Payout 4|
|Dividend per stock||$0.40 per stock||Pending||Pending||Pending|
What is the dividend yield for Pfizer over the last 10 years?
The yield on Pfizer shares is obtained by dividing the annual dividend by the annual average price.
A stock's yield provides key information about a company's dividend policy and its evolution over time and performance.
Annual gross shareholder return = Total dividend for the year ÷ average share price for the same year
The 10-year average return = Sum of annual returns ÷ 10
What analysts are saying about Pfizer stock:
A critical analysis of Pfizer stock:
The Pfizer Group currently has solid fundamentals that are mainly sending positive signals with the following elements
- An excellent EBITDA/Sales ratio: this ratio appears to be significant with high margins before depreciation, amortization and taxes.
- A profitable business: the company's business shows strong profitability with high net margins.
- Strong financial position: Pfizer shows a very positive financial position with strong investment capabilities.
- Excellent valuation: The group's P/E for the current fiscal year is 7.44 and 10.2 for fiscal year 2023, which suggests a cheap valuation of the stock in terms of earnings multiples. The company also appears to be poorly valued in terms of cash flow.
- Upwardly revised expectations: Over the past year, analysts have repeatedly revised upward their forecasts for the company's revenue and business development as well as their profitability estimates for the coming years.
- Earnings per share are also expected to increase based on current analyst forecasts.
- Average price target down: However, analysts have also recently revised their average price target downward.
- Strong variations in analysts' opinions: we also note that the opinions and price targets of the various analysts who cover this issue are inconsistent, which reflects a difficulty in evaluating the company's activities.
- Disappointing publications: Finally, Pfizer has historically published below expectations and consensus.
A technical analysis of Pfizer stock:
Let's now look at the technical analysis of this Pfizer share. This one indeed sends strong buy signals on this stock in the medium and long-term with the following indicators:
- The RSI indicator is currently at 57.63, which is a strong buy signal.
- The short and medium-term stochastic indicators are also sending a buy signal although more moderate and the long-term stochastic is the only oscillator sending a sell signal.
- The MACD is currently at the 3.74 level and is also sending a buy signal.
- The MA5 simple and exponential moving average is sending a sell signal and all other moving averages are sending a strong buy signal.
- The next technical support levels for this stock are at 43.51 and 40.09 and the next resistance levels are located at 52.24 and 57.65
Who is Pfizer?
The Pfizer Group Inc. is an American pharmaceutical company that is currently the world leader in its field.
The group has several types of activities and develops and markets pharmaceutical and healthcare products worldwide.
The Pfizer Group's turnover can be broken down by product category as follows
- Vaccines with 52.4% of sales
- Cancer drugs with 15.2% of sales
- Cardiovascular, metabolic and analgesic drugs with 11.5% of sales
- Injectable drugs, anti-infectives and active pharmaceutical ingredients with 9% of sales
- Drugs for inflammatory and immune diseases with 5.5% of sales
- Drugs for rare diseases with 4.4% of sales
- Other drugs with 2% of sales
Pfizer currently has more than 39 production sites for its treatments around the world and employs more than 79,000 people.
The geographical distribution of the Pfizer Group's sales is as follows
- The United States with 36.6% of sales
- Europe with 22.6% of sales
- The rest of the world with 40.8% of sales
Who are Pfizer’s competitors?
While Pfizer is currently the global leader in its market, it faces strong competition from other companies in the industry. Here are its main current competitors:
- AstraZeneca: the Swedish-British pharmaceutical group is the result of the 1999 merger of the Swedish company Astra and the British laboratory Zeneca.
- BioNTec: this German biotech company specializes in the development and production of active immunotherapies for the treatment of serious diseases.
- Moderna: this American biotech company was founded in 2010 and mainly develops protein therapies based on messenger RNA technology.
- AbbVie: this US-based research-based pharmaceutical company develops drugs for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of cystic fibrosis, testosterone deficiency and complications of kidney disease.
- Novartis: This Swiss pharmaceutical company was formed in 1996 from the merger of Ciba-Geugy and Sandoz and is now based in Basel.
- Merck: this German company based in Darmstadt is active in both the pharmaceutical and chemical sectors.
- Roche Holding: this Swiss pharmaceutical company is one of the world leaders in this sector and operates in two parallel divisions, one for pharmaceuticals and the other for diagnostics.
Who are Pfizer’s partners?
In its recent history, Pfizer has formed numerous strategic alliances with other companies in its industry or related sectors. Its most recent partners include:
- BioNTech: Of course, the two companies recently collaborated on the development of a vaccon against Covid-19, based on messenger RNA technology with a material transfer and collaboration agreement.
- Acuitas Therapeutics: another partnership has been signed with this specialist in lipid nanoparticles used in vaccines and other messenger RNA treatments. Pfizer has been granted a license option on up to 10 targets from the Acuitas portfolio.
- Sanofi: another partnership signed in the context of the Covid pandemic was with the French laboratory Sanofi, from which it received support for the production of its vaccine and for the supply of the European Union.
- DirectoSuivi: Pfizer has also selected this remote monitoring solution to strengthen and optimize the remote link between cancer patients and healthcare teams and will enable it to offer an innovative remote support and care solution.
- PostEra: another partnership has been set up with this biotech company specializing in machine learning solutions for research and to accelerate the evolution of small molecule drugs through the development of a technological platform based on generative chemistry.
- Unicancer: Finally, a partnership has been signed between these two companies for an initial period of three years to better understand the management of patients suffering from metastatic breast cancer with real-life data from the ESME Metastatic Breast Cancer program.